Tag - Roy Buchanan

Developments

JMP sees Phase 1 results for Roche’s antibody encouraging for iBio’s IBIO-101

JMP Securities, in a new report, writes that the promising mechanistic and clinical activity for Roche’s drug candidate, RG6292, should support advancement of iBio’s (NYSEA:IBIO) IBIO-101. IBIO-101 is an anti-CD25...

April 17, 2023

Markets

JMP starts Pardes Biosciences at MO; PT $9

JMP Securities initiated coverage of Pardes Biosciences (NASDAQ:PRDS) with a “market outperform” rating and price target of $9. The stock closed at $1.15 on Dec. 12. Pardes is developing PBI-0451 as a potential novel...

December 13, 2022

Markets

JMP starts iBio at market outperform; PT $1.50

JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology...

November 29, 2021

Tag - Roy Buchanan

JMP sees Phase 1 results for Roche’s antibody encouraging for iBio’s IBIO-101

JMP starts Pardes Biosciences at MO; PT $9

JMP starts iBio at market outperform; PT $1.50

General

More